Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer

PURPOSE: This study analyzed the role of plasma biomarkers for TSU-68 in a previous phase II trial comparing TSU-68 plus docetaxel and docetaxel alone in patients with metastatic breast cancer. MATERIALS AND METHODS: A total of 77 patients were eligible for this study (38 in the TSU-68 plus docetaxe...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Res Treat
Auteurs principaux: Yoo, Changhoon, Kim, Sung-Bae, Ro, Jungsil, Im, Seock-Ah, Im, Young-Hyuck, Kim, Jee Hyun, Ahn, Jin-Hee, Jung, Kyung Hae, Song, Hong Suk, Kang, Seok Yun, Park, Hee Sook, Chung, Hyun-Cheol
Format: Artigo
Langue:Inglês
Publié: Korean Cancer Association 2016
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4843716/
https://ncbi.nlm.nih.gov/pubmed/26194374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2015.089
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires